Results from Phase III study evaluating oral otezla or injectable etanercept versus placebo in patients with moderate to severe plaque psoriasis

Celgene Corporation has announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4)...